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Abstract The ordered, directional migration of T-lympho-
cytes is a key process during immune surveillance, immune
response, and development. A novel series of pyrrolo-1,5-
benzoxazepines have been shown to potently induce
apoptosis in variety of human chemotherapy resistant
cancer cell lines, indicating their potential in the treatment
of both solid tumors and tumors derived from the
hemopoietic system. Pyrrolobenzoxazepine 4-acetoxy-5-
(1-naphtyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]-oxazepine
(PBOX-15) has been shown to depolymerize tubulin in
vitro and in the MCF7 breast cancer cell line. We
hypothesized that this may suggest a role for this compound
in modulating integrin-induced T-cell migration, which is
largely dependent on the microtubule dynamics. Experi-
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ments were performed using human T lymphoma cell line
Hut78 and peripheral blood T-lymphocytes isolated from
healthy donors. We observed that human T-lymphocytes
exposed to PBOX-15 have severely impaired ability to
polarize and migrate in response to the triggering stimulus
generated via cross-linking of integrin lymphocyte function
associated antigen-1 receptor. Here, we show that PBOX-15
can dramatically impair microtubule network via destabili-
zation of tubulin resulting in complete loss of the motile
phenotype of T-cells. We demonstrate that PBOX-15
inhibitory mechanisms involve decreased tubulin polymer-
ization and its post-translational modifications. Novel
microtubule-targeting effects of PBOX-15 can possibly open
new horizons in the treatment of overactive inflammatory
conditions as well as cancer and cancer metastatic spreading.
Keywords T-cell migration . PBOX . Tubulin
Introduction
T-lymphocytes are the central regulatory cells of the
immune response and require distinct signals for activation.
After leaving the vasculature, T-cells acquire a polarized
morphology and initiate crawling, probably as a result of
chemotactic stimuli, earlier activating stimuli or both [1].
The chemotactic ‘hand-mirror’ shape of a crawling T-cell
consists of a flattened leading edge followed by the nucleus
and a handle-like tail termed the uropod [2]. The intrinsic
ability of T-lymphocytes to migrate has been observed in
vivo within lymph nodes and also in in vitro models of
migration [3–6]. T-cell migration from the vascular com-
partment across tissue barriers and through the extracellular
matrix is a key event during inflammation. The capacity to
migrate and localize in tissues is of vital importance for the
protective function of lymphocytes against infectious
agents. However, the capacity of lymphocytes to migrate
and infiltrate tissues is also a major contributing factor in
the development of autoimmunity, allergy and graft
rejection. In addition, tissue specific accumulation is a
feature of some neoplastic lymphocytes.
Lymphocyte migration and homing requires a series of
ligand-receptor interactions involving adhesion molecules
of the integrin family [7]. T-cells make use of the integrin
lymphocyte function associated antigen-1 (LFA-1) when
migrating in response to chemoattractants either across the
vasculature into lymph nodes or across the vessels
associated with inflamed tissues [8]. These transmembrane
proteins connect the extracellular matrix with the cell
interior both physically, being linked to cortical cytoskel-
eton, and functionally, serving as bi-directional signal
transducers. By engagement with intracellular adhesion
molecules, LFA-1 provides a strong adhesive force to
promote T-cell and antigen presenting cell conjugate
formation and generally stabilize this interaction. Locomo-
tory T-cells triggered via LFA-1 in the absence of
chemotactic gradient produce movement in a random
manner [8]. In addition, LFA-1 has the ability to transduce
a variety of transmembrane signals including protein kinase
C activation [6] and cytoskeletal rearrangement [9].
However, the exact sequence of integrin-mediated signaling
events resulting in cytoskeletal rearrangements and cell
locomotion is not fully understood.
Microtubules (MTs) are essential components of the
cytoskeleton and are important for many aspects of mamma-
lian cell responses including cell division, growth, migration,
and signaling [10, 11]. The MTs play a key role in T-cell
locomotion. MT retraction into the cellular uropod is an
important step in T-cell motility [8]. MT-targeting agents thus
can affect migration of malignant T-cells into endothelial
monolayers. Tubulins, the building block of MTs, are subject
to specific post-translational modifications including acetyla-
tion, detyrosination, and tyrosination [12, 13]. These post-
translational modifications of tubulins are thought to
modulate the functions and localization of MTs within the
cell.
MTs are necessary for directed migration of endothelial
and other cells, and there are several possible mechanisms
by which MT-disrupting compounds could block cell
motility. These include impairment of the repositioning of
the microtubule organizing center (MTOC), interfering MT
interaction with focal adhesions, inhibition of MT poly-
merization, and depolymerization cycle, inhibition of
intracellular protein trafficking and vesicle transport, and
inhibition of MT-mediated integrin clustering and increased
avidity. These processes vary in their sensitivity to
inhibition by MT-targeting drugs. Therapeutic agents that
target cytoskeletal proteins inhibit T-cell migration [14].
This inhibition of T-cell migration could be exploited
therapeutically in autoimmune T-cell infiltrative diseases.
MT-targeting agents like taxol and nocodazole are being
used clinically both as anti-inflammatory and anticancer
drugs. It has also been established through various and
clinical studies that drug possessing anticancer activity also
exhibit anti-inflammatory properties.
Our research center has developed and reported a novel
series of pyrrolo-1,5-benzoxazepine (PBOX) compounds
which induce apoptosis in a wide variety of human
chemotherapy resistant cancer cells including those derived
from hematological malignancies, breast carcinomas, and
chronic myeloid leukemia cells [15–20]. Furthermore,
PBOX compounds demonstrated significant anti-tumor
activity in vivo in an aggressive murine model of mammary
carcinoma that has been developed in our research center
[15]. These suggest the potential of these drugs as novel
anticancer therapeutics in the treatment of both solid tumors
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and tumors derived from the hematopoietic system. Current
on-going investigations are aimed to characterize the
molecular mechanisms by which these drugs induce
apoptosis of cancer cells. It has recently been demonstrated
that some of the PBOX compounds targeted microtubule
network in human breast carcinoma-derived MCF7 cells
and inhibited the assembly of purified tubulin in vitro [21].
Therefore, the aim of this study was to investigate the effect
(s) of a novel microtubule-targeting agent Pyrrolobenzox-
azepine 4-acetoxy-5-(1-naphtyl)naphtho[2,3-b]pyrrolo[1,2-
d][1,4]-oxazepine (PBOX-15) on active T-cell migration,
which is largely dependent on MT dynamics [8].
Materials and methods
Materials
PBOX-15 was developed by Campiani’s research group
according to a previously described procedure [22]. (Roswell
Park Memorial Institute) RPMI 1640 medium, fetal bovine
serum (FBS), and L-glutamine were from Gibco BRL
(Grand Island, NY, USA). Antibodies used for induction of
T-cell motility as previously described [6] were of the clone
SPVL7 (mAb to the α–chain of LFA-1 from Sanbio). Goat
anti-mouse IgG was obtained from Dako A/S (Denmark).
Human recombinant ICAM-1Fc (rICAM-1) was purchased
from R&D Systems (Minneapolis, MN, USA). Mouse
monoclonal anti-α-tubulin, anti-acetylated tubulin (clone 6-
11B-1) and anti-tyrosinated tubulin (TUB-1A2) antibodies
were purchased from Sigma (St Louis, MO, USA). Rabbit
polyclonal anti-detyrosinated tubulin (Glu-tubulin) was
obtained from Chemicon (Millipore Corporation, Billerica,
MA, USA). Alexa fluor 488 conjugated anti-mouse was
from Molecular Probes (Invitrogen Corporation, CA, USA).
Lymphoprep® was obtained from Axis-Shield PoC AS
(Oslo, Norway). Polyvinylidene fluoride (PVDF) membrane
was obtained from Pall Gelman Laboratories (Ann arbor, MI,
USA). Acrylamide–bisacrylamide solution, Acrylogel (30%)
was purchased from BDH (VWR International Ltd., Eng-
land). Enhanced chemiluminescence (ECL) plus reagent was
purchased from Amersham (Arlington Heights, IL, USA).
All the reagents unless attributed specifically, were from
Sigma (St Louis, MO, USA).
Cell cultures
Human cutaneous T lymphoma cell line Hut78 (American
Type Culture Collection (ATCC), Manassas, VA, USA) was
used and cultured as described previously [6]. Briefly, they
were cultured in RPMI 1640 medium containing 10% (v/v)
heat inactivated FBS, L-glutamine, and antibiotics (penicil-
lin 100 IU/ml, streptomycin 100 μg/ml) in 5% CO2 at 37°C.
Peripheral blood T-lymphocytes (PBTLs) were isolated
from healthy donors using standard techniques. Briefly,
peripheral blood mononuclear cells were prepared using
Lymphoprep®. T-cells were expanded by culturing in
RPMI 1640 medium containing 10% (v/v) heat inactivated
FBS in the presence of 1 μg/ml phytohemagglutin for
3 days. These cells were then maintained in culture medium
supplemented with 20 ng/ml IL-2. After 10 days, PBTLs
population were >95% positive for CD3.
Induction of cell motility
The ability of T-cells to display integrin-induced locomo-
tory behavior was determined using our well-characterized
assay as previously described [6]. Briefly, 6- or 96-well
tissue culture plates, depending on the particular assay type
were pre-coated with goat anti-mouse IgG or mouse anti-
human Fc and subsequently incubated with cross-linking
monoclonal motility inducing anti-LFA-1 antibody (clone
SPVL-7) or human rICAM-1. Cells were loaded into the
anti-LFA-1 coated wells (60×104 cells/well in 6-well plate
or 10×103 cells/well in 96-well plate for Hut78 cells; 30×
103 cells/well in 96-well plate for PBTLs).
Using previously described procedure, rICAM-1 cross-
linking of PBTLs following LFA-1 activation was performed
[23] with minor modifications. Briefly, 10 days old cultures
were washed twice in wash buffer (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) 20 mM (pH 7.4),
NaCl 140 mM, glucose 2 mg/ml). Cells were then
resuspended in activation buffer (HEPES 20 mM (pH
7.4), NaCl 140 mM, glucose 2 mg/ml, MgCl2 5 mM, and
ethylene glycol tetraacetic acid (EGTA) 1 mM) prior to
being loaded into the rICAM-1 coated tissue culture plates.
As a control (resting cells), wells were coated with poly-
L lysine (cells adhered to this surface without activation).
Cells were pretreated with indicated compounds for 30 min
at 37°C before being seeded. PBOX-15 was dissolved in
ethanol to the stock concentration of 10 mM and stored at -
20°C. Subsequent working dilutions, as indicated in the
text, were prepared extemporarily in the culture medium.
Control, untreated cells received equivalent volumes of the
appropriate solvent.
Deformation Index
In order to study migratory phenotype of T-cells, Deforma-
tion Index (DI) was calculated as described previously [24].
DI provides a stronger measure of the degree of cell
polarization in comparison to elongation index and circu-
larity alone and, therefore, more accurately reflects the
phenotype of polarized locomotory cells. Typically, values
of 1–3 are assigned to cells that were non-migratory, i.e.,
cell shape is nearing circular. Those cells that display a
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polarized phenotype (cell body and trailing uropod) and,
therefore, a higher degree of deformation had higher DI
values (>5) [24]. On average, >40 randomly chosen cells
were scored for each set of conditions. Semi-automated
analysis was performed using the Scion Image software
(Scion Corporation, Fredrick, MC, USA).
Preparation of cellular extracts of Hut78 cells
for immunoblotting
The cellular extracts were prepared as described previously
[25] with minor modifications. Briefly, cells were washed
with ice-cold phosphate-buffered saline (PBS) and lysed in
lysis buffer (HEPES 50 mM (pH 7.4), NaCl 150 mM,
MgCl2 1.5 mM, EGTA 1 mM, sodium pyrophosphate
10 mM, sodium fluoride 50 mM, β-glycerophosphate
50 mM, Na3VO4 1 mM, 1% Triton X-100, phenylmethyl-
sulphonyl fluoride 2 mM, leupeptin 10 μg/ml and aprotinin
10 μg/ml). Lysis was carried out at 4°C for 30 min. Lysates
were centrifuged at 16,000×g for 15 min at 4°C. The protein
content of the supernatant was determined by Bradford
assay. Cell lysates were boiled with Laemmli sample buffer
(final concentration: Tris-HCl 62.5 mM (pH 6.7), Glycerol
10% (v/v), sodium dodecyl sulfate 2% (w/v), bromophenol
blue 0.002% (w/v) containing β-mercaptoethanol 143 mM)
for 5 min. Equal amounts of lysates were resolved by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). The transfer of separated proteins to PVDF
membrane was performed by semi-dry blotting. The PVDF
membranes were blocked with blocking buffer containing
5% dry milk in PBST (0.1% (v/v) Tween-20 in PBS) at
room temperature for 1 h. Following blocking of the
membrane, the immunoblot was incubated with the indicat-
ed primary antibody overnight at 4°C, followed by
incubation with horseradish peroxidase conjugated second-
ary antibody for 1 h at room temperature. The immunoblots
were visualized using the ECL detection system.
Immunofluorescence microscopy
Confocal microscopy was performed as previously de-
scribed [6]. Resting or LFA-1 stimulated cells (as described
above) on the poly-L lysine or anti-LFA-1-coated Lab-Tek
multi-chamber Permanox® slides (Nalge Nunc Internation-
al, Rochester; NY, USA) were fixed by incubating with 3%
paraformaldehyde in PBS for 30 min. Cells were washed
twice in PBS for 10 min and were permeabilized in 0.5%
Triton X-100 before staining. Cells were incubated with
primary antibody for 2 h, washed thrice with PBS, and then
incubated with secondary antibodies and Hoechst for 1 h at
room temperature. Slides were finally washed with PBS,
drained, and mounted with DAKO fluorescent mounting
medium (Dako A/S, Denmark). Fluorescent microscopy
was performed using 100X objective on a Perkin Elmer
LCI confocal workstation with a Kr–Ar laser attached to a
Nikon TE2000-U inverted microscope (Nikon, Tokyo,
Japan) under Ultraview (Perkin Elmer) image acquisition
software. At least 20 different microscopic fields were
observed for each sample.
Ex vivo polymerized tubulin assay
The evaluation of tubulin polymerization in live cells (ex
vivo assay) was performed as previously described [26].
Briefly, untreated or PBOX-15-treated resting and migrat-
ing HUT78 cells (as explained above) were harvested into
MT-preserving buffer [Pipes 0.1 M (pH 6.9), glycerol 2 M,
MgCl2 5 mM, EGTA 2 mM, 0.5% Triton X-100, and
protease inhibitors) supplemented with 4 μM taxol to
maintain stability of assembled MTs during isolation. The
supernatant containing unpolymerized tubulin was clarified
by centrifugation (20,000 g for 45 min) and separated from
the pellet containing sedimented polymerized tubulin. The
pellet was washed once in MT-preserving buffer before
being denatured in Laemmli sample buffer.
Densitometric analysis
Densitometric analyses of the western blots were performed
by using GeneTools software (Syngene, Cambridge, UK).
The relative values of the samples were determined by
giving an arbitrary value of 1.0 to the respective control
samples of each experiment.
Statistical analysis
The data are expressed as mean ± SEM. For comparison of
two groups, p-values were calculated by two-tailed un-
paired student’s t-test. In all cases p<0.05 was considered
to be statistically significant.
Results
PBOX-15 inhibits T-cell migration
Activated T-lymphocytes triggered via LFA-1 receptor or
ligand interaction rapidly polarize and acquire active motile
behavior [6]. They start spreading and subsequently
undergo dramatic cytoskeletal changes resulting in a
polarized phenotype with long cytoplasmic projections
[8]. To test the effect of PBOX-15 on T-cell migration,
Hut78 cells were pretreated with different concentrations of
PBOX-15 for 30 min and incubated on anti-LFA-1-coated
96-well plates for 4 h. Control untreated cells developed a
polarized and elongated morphology (Fig. 1a). Pretreatment
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of Hut78 cells with different concentrations of PBOX-15
ranging from 0.2 to 1 μM resulted in the inhibition of LFA-
1-induced migration in a dose-dependent manner (Fig. 1b–e).
At 1 μM concentration of PBOX-15, complete loss of the
locomotion-associated phenotype was observed (Fig. 1e).
Quantitation of the observed inhibitory effect of PBOX-15
using DI as a quantitative descriptor of cell morphology
also indicated that the development of motile phenotype
was inhibited by PBOX-15 in a dose-dependent manner
(Fig. 1f).
To test the in vivo efficacy of PBOX-15, we determined
whether the inhibitory effect was present in LFA-1-
stimulated PBTLs migration. Normal human PBTLs isolat-
ed from a healthy donor showed active locomotory
behavior when exposed to anti-LFA-1 ligands. (Fig. 2a).
Pretreatment of PBTLs with different concentrations of
PBOX-15 resulted in the inhibition of migration in a dose-
dependent manner (Fig. 2b–f) with complete loss of
migration at 1 μM (Fig. 2e), as observed with Hut78 cells.
Similar inhibitory effect of PBOX-15 was observed with
LFA-1-activated human PBTLs when exposed to immobi-
lized rICAM-1 ligands (data not shown).
To test the potential apoptotic effect of PBOX-15, Hut78
cells were treated with 1 μM concentration of PBOX-15 for
30 min or 24 h. No cell death was observed after 30 min of
the treatment (Supplementary Fig. 1). However, treatment
of the cells for 24 h induced apoptosis up to 37%, as
detected by flow-cytometry after Annexin V and propidium
iodide labeling (Supplementary Fig. 1). Therefore, for
further experimentation, short pretreatment of the cells with
1 μM concentration of PBOX-15 for 30 min was employed.
Further, to determine if the failure of T-cells to develop a
migratory phenotype was also accompanied by the loss of
active locomotion, high content analysis experiments utilizing
time-lapse video imaging by InCell-1000 Analyzer (GE
Healthcare, England) were performed. A slow and apparently
random mode of locomotion was observed in control Hut78
cells triggered via cross-linking of LFA-1. Measuring live cell
migration over a period of 20 min gave a clear evidence that
PBOX-15 treatment significantly decreased LFA-1 stimulated
Hut78 cells migration (Supplementary Fig. 2). Average speed
of Hut78 cell migration was recorded to be 1.055 μm/min
which was decreased by 65.4% when were pretreated with
PBOX-15 (0.365 μm/min). Average distance traveled by
control cells was 21.1 μm (ranging from 8.3 to 69.5 μm),
which was decreased to 7.3 μm (ranging from 0.1 to
42.1 μm) when cells were pretreated with PBOX-15
(Supplementary Fig. 2a vs b).
PBOX-15 targets microtubules of T-cells
Microtubules represent a central cytoskeleton system
controlling active locomotion in T-cells. Recent studies
from our laboratory provided evidences that PBOX-15
induces apoptosis by affecting tubulin polymerization [21].
To determine whether PBOX-15 exerts similar effects on T-
cells microtubules causing inhibition of its migration,
intracellular distribution and functional involvement of the
microtubule were analyzed. Control untreated resting Hut78
cells showed radial arrays of organized tubulin distribution
at the centrosome (Fig. 3a). When the Hut78 cells were
stimulated with LFA-1, the characteristic array of MT was
Fig. 1 Effect of PBOX-15 on
LFA-1-induced locomotory
phenotype of Hut78 cells. Cells
were pretreated with either ve-
hicle [0.1% (v/v) ethanol; con-
trol] (a), PBOX-15 0.2 μM (b),
0.4 μM (c), 0.6 μM (d), or
1.0 μM (e) for 30 min and
incubated on anti-LFA-1 coated
96-well plate for 4 h. Experi-
ments were performed in tripli-
cate and repeated three times. At
least 20 microscopic fields were
photographed, and a representa-
tive figure is shown. Dose-
response migration inhibition by
PBOX-15 in Hut78 cells stimu-
lated via immobilized anti-LFA-1
was determined by measurement
of DI (f). Data are mean ± SEM
of three independent experi-
ments. *p<0.05 with respect to
control
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displayed, in that MTOC was located at the side of the
nucleus opposing the direction of cell migration and long
MT extended to the uropods from here, reflecting the state
of cell polarization (Fig. 3b). In contrast, exposure of Hut78
cells to PBOX-15 dramatically impaired the tubulin network
resulting in complete loss of the typical motile phenotype
upon LFA-1 ligation. PBOX-15 treated T-cells displayed
disorganized tubulin with thin discontinuous filaments and
disrupted staining; microtubules were no longer radiating
from the centrosome to the plasma membrane (Fig. 3c,d).
Similar effects were observed when Hut78 cells were
pretreated with microtubule depolymerizing agent nocoda-
zole (Fig. 3e,f). In contrast, stable microtubules in bundles
were observed when cells were pretreated with paclitaxel, a
microtubule stabilizing drug (Fig. 3g,h).
A similar tubulin-targeting effect of PBOX-15 was
observed in resting as well as LFA-1 stimulated PBTLs
(data not shown). PBOX-15 did not significantly affect
actin cytoskeletal network (Supplementary Fig. 3).
Effects of PBOX-15 on post-translational modifications
of tubulin in T-cells
Acetylated tubulins and tyrosinated tubulins are related to
microtubule stability and dynamics [27, 28]. To further
explore the effect of PBOX-15 on post-translational
modification of tubulin in T-cells during LFA-1-induced
migration, PBOX-15 treated or untreated resting and LFA-1
stimulated Hut78 cells were immunostained with antibody
directed against acetylated α-tubulin (Fig. 4). Untreated
control resting cells showed uniform distribution of
acetylated tubulin radiating from the centrosome (Fig. 4a);
however, this subset of microtubule was dramatically
reduced when Hut78 cells were allowed to migrate upon
LFA-1 cross-linking (Fig. 4b). Its localization was limited
to the area near the MTOC with a characteristic spindle-like
appearance (Fig. 4b). When these cells were treated with
PBOX-15, the detectable levels of acetylated tubulin were
reduced and it was localized as a compact spot near the
MTOC in the resting cells (Fig. 4c). Moreover, when
PBOX-15-treated cells were cross-linked with LFA-1,
tubulin acetylation was further reduced and was only hardly
visible around the MTOC (Fig. 4d). As post-translational
acetyl modification correlates with increased MT stability
[28], these results indicate that the PBOX-15 destabilized
long life MTs. Similar effects were observed when Hut78
cells were pretreated with nocodazole (Fig. 4e,f). Paclitaxel
treatment stabilized acetylated tubulin and was observed in
microtubule bundles in resting as well as LFA-1 cross
linked cells (Fig. 4g,h).
Tyrosinated tubulin represents the major form of active
microtubules in cells [29]. Therefore, we used an antibody
directed against tyrosinated form of tubulin to observe
changes in this subset of microtubule in Hut78 cells.
Untreated resting as well as LFA-1-stimulated Hut78 cells
showed intense labeling for tyrosinated tubulin, which was
distributed throughout the cell body radiating from the
MTOC (Fig. 5a,b). Strikingly, tyrosinated tubulin network
of Hut78 cells after PBOX-15 treatment appeared collapsed
with disorganized and punctate staining (Fig. 5c,d),
apparently due to the depolymerization of both dynamic
and stable microtubules. Similar effects were observed
Fig. 2 Effect of PBOX-15 on
LFA-1-induced locomotory
phenotype of PBTLs. PBTLs
isolated from healthy donor
were pretreated with either ve-
hicle [0.1% (v/v) ethanol; con-
trol] (a), PBOX-15 0.2 μM (b),
0.4 μM (c), 0.6 μM (d) or
1.0 μM (e) for 30 min and
incubated on anti-LFA-1-coated
96-well plate for 1 h. Experi-
ments were performed in tripli-
cate and repeated three times. At
least 20 microscopic fields were
photographed, and a representa-
tive figure is shown. Dose-
response migration inhibition by
PBOX-15 in Hut78 cells stimu-
lated via immobilized anti-LFA-1
was determined by measurement
of DI (f). Data are mean ± SEM




when Hut78 cells were pretreated with nocodazole (Fig. 5e,f).
However, stable microtubules bundles formed due to
paclitaxel treatment stained for localized tyrosinated tubulin
(Fig. 5g,h).
As carboxy-terminal (C-terminal) tyrosine is encoded for in
most α-tubulin by the messenger RNA, the primary modifi-
cation is its removal by tubulin tyrosine carboxypeptidase
[27]. The resulting detyrosinated tubulin exposes a carboxy-
terminal glutamic acid and is therefore referred to as Glu-
tubulin. Glu-tubulin is abundant in stable MTs of various cell
types. Although detyrosination itself does not stabilize MTs,
it can be used as a marker for how long an MT has been
assembled [27]. Untreated resting cells showed intense
staining for Glu-tubulin towards leading edge of cells
(Fig. 6a). Glu-tubulin was abundant in LFA-1-stimulated
untreated cells toward the leading edge and MTOC (Fig. 6b).
Detyrosinated subset of tubulin in Hut78 cells after PBOX-15
treatment appeared collapsed and disorganized (Fig. 6c,d).
Similar effects were observed when Hut78 cells were
pretreated with nocodazole (Fig. 6e,f). Paclitaxel treatment
stabilized the tubulin, making Glu-tubulin appear as bundles
(Fig. 6g,h).
To further confirm these results biochemically, we
examined the total expression of α-tubulin, acetylated α-
tubulin, and tyrosinated tubulin by western blotting. Initially,
we examined the total expression of α-tubulin in resting and
LFA-1-stimulated Hut78 cells treated with or without PBOX-
15 (Fig. 7a). Densitometric quantitation of α-tubulin bands,
normalized for glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) expression, indicated that there was no significant
difference between these samples (not depicted). Acetylated
α-tubulin level in LFA-1 stimulated Hut78 cells was 57%
lower as compared with resting cells (Fig. 7b; open bars,
lanes 2 vs 1). When these cells were pretreated with PBOX-
15, acetylated tubulin was reduced to 47% in resting Hut78
cells (Fig. 7b; open bars, lanes 3 vs 1), which was further
reduced to 25% after LFA-1 cross-linking as compared to
control untreated resting cells (Fig. 7b; open bars, lanes 4 vs
1). Tyrosinated tubulin level in migrating Hut78 cells was
increased up to 47% compared to the resting cells (Fig. 7b;
closed bars, lanes 2 vs 1). Treatment of these cells with
PBOX-15 reduced the level of tyrosinated tubulin by 49%
in resting (Fig. 7b; closed bars, lanes 3 vs 1) and by 46%
upon LFA-1 cross-linking as compared to control (untreat-
ed) cells (Fig. 7b; closed bars, lanes 4 vs 1).
Fig. 3 Effect of PBOX-15 on the organisation of cellular MT network
in resting and LFA-1 stimulated T-cells. Hut78 cells were pretreated
with either vehicle [0.1% (v/v) ethanol] (a, b), 1.0 μM PBOX-15 (c,
d), 10.0 μM nocodazole (e, f) or 4.0 μM paclitaxel (g, h) for 30 min
and incubated on poly-L lysine (a, c, e, g) or anti-LFA-1 (b, d, f, h)
coated Permanox® chamber slides for 4 h. After this time, the medium
was carefully removed and cells were fixed in 3% PFA. Cells were
incubated with mouse monoclonal anti-α-tubulin antibody for 1 h and
then with Alexa488 conjugated anti-mouse secondary antibody for
further 1 h at room temperature. After washing, nuclei of the cells
were stained with Hoechst (blue). The organisation of MT network
(green) was visualized by confocal microscopy using a 100× oil
immersion lens. Arrow indicates clearly distinguishable MTOC.
Results shown are representative of three independent experiments

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PBOX-15 induced alterations in tubulin polymerization
dynamics
Because PBOX-15 markedly disrupted the cellular micro-
tubule network, we investigated whether it could affect
tubulin polymerization in live cells. The effect of PBOX-15
on the live cell tubulin dynamics has not yet been reported.
Hence, to study the dynamics of microtubule formation ex
vivo, Hut78 cells pretreated with or without PBOX-15 were
stimulated by incubating on anti-LFA-1 coated plate for 4 h
or left unstimulated and lysed. As MTs could be partially
destroyed during the preparation of crude cell lysates, we
lysed the cells in MT-preserving buffer and performed
differential sedimentation of polymerized tubulin (pellet
Fig. 4 Effect of PBOX-15 on
the acetylation of tubulin in
resting and LFA-1 stimulated T-
cells. Hut78 cells were pre-
treated with either vehicle
[0.1% (v/v) ethanol] (a, b),
1.0 μM PBOX-15 (c, d),
10.0 μM nocodazole (e, f) or
4.0 μM paclitaxel (g, h) for
30 min and incubated on poly-L
lysine (a, c, e, g) or anti-LFA-1
(b, d, f, h) coated Permanox®
chamber slides for 4 h. After this
time, the medium was carefully
removed and cells were fixed in
3% PFA. Cells were incubated
with mouse monoclonal anti-
acetylated tubulin antibody for
1 h and then with Alexa488
conjugated anti-mouse second-
ary antibody for further 1 h at
room temperature. After wash-
ing, nuclei of the cells were
stained with Hoechst (blue).
Acetylated tubulin (Ac-tubulin;
green) was visualized by confo-
cal microscopy using a 100× oil
immersion lens. Arrow indicates
clearly distinguishable MTOC.




fraction) from unpolymerized free tubulin (supernatant
fraction) pool. Western blot analysis (Fig. 8a) showed that
when untreated Hut78 cells were stimulated with LFA-1,
the level of unpolymerized tubulin was reduced down to
64% (Fig. 8b; lanes 1 vs 3), with a concomitant increase of
polymerized tubulin from 40% to 110% (Fig. 8b; lanes 5 vs
7). In resting Hut78 cells, treatment with PBOX-15
increased the amount of unpolymerized tubulin up to 44%
(Fig. 8b; lanes 1 vs 2), with simultaneous decrease of
polymerized tubulin level from 40% to 6% (Fig. 8b; lanes 5
vs 6). In a similar manner, when PBOX-15-treated Hut78
cells were stimulated with LFA-1, the level of unpolymer-
ized tubulin was increased from 64% to 139% (Fig. 8b;
lanes 3 vs 4), with simultaneous decrease of polymerized
tubulin level from 110% to 11% (Fig. 8b; lanes 7 vs 8).
Taken together, these results demonstrate that PBOX-15
inhibits T-cell migration by depolymerizing microtubules. It
disrupts the microtubule network, interferes with post-
Fig. 5 Effect of PBOX-15 on
the tyrosination of tubulin in
resting and LFA-1 stimulated T-
cells. Hut78 cells were pre-
treated with either vehicle
[0.1% (v/v) ethanol] (a, b),
1.0 μM PBOX-15 (c, d),
10.0 μM nocodazole (e, f) or
4.0 μM paclitaxel (g, h) for
30 min and incubated on poly-L
lysine (a, c, e, g) or anti-LFA-1
(b, d, f, h) coated Permanox®
chamber slides for 4 h. After this
time, the medium was carefully
removed and cells were fixed in
3% PFA. Cells were incubated
with mouse monoclonal anti-
tyrosinated tubulin antibody for
1 h and then with Alexa488
conjugated anti-mouse second-
ary antibody for further 1 h at
room temperature. After wash-
ing, nuclei of the cells were
stained with Hoechst (blue).
Tyrosinated tubulin (Tyr-
tubulin; green) was visualized
by confocal microscopy using a
100× oil immersion lens. Arrow
indicates clearly distinguishable
MTOC. Results shown are rep-
resentative of three independent
experiments
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translational modifications of tubulin, and suppresses
microtubule dynamics, thus, affecting the function of this
cytoskeletal system.
Discussion
PBOX-15 is a potent proapoptotic member of the novel
series of PBOX compounds which has previously been
shown to induce apoptosis in many human tumor cell lines
and to have anticancer properties in various cell culture
systems, animal models, and clinical samples [15–19]. The
mechanisms by which PBOX-15 exert its antiproliferative
effects have been attributed to tubulin depolymerizing
activity, thus, resulting in cell death by apoptosis [21]. We
demonstrate here that PBOX-15 inhibits LFA-1 integrin-
induced migration of human T lymphoma cell line Hut78 as
well as PBTLs. The observed effect was dramatic, leading
to a complete loss of LFA-1-mediated T-cell polarization
and migration.
Fig. 6 Effect of PBOX-15 on
the detyrosination of tubulin in
resting and LFA-1 stimulated T-
cells. Hut78 cells were pre-
treated with either vehicle
[0.1% (v/v) ethanol] (a, b),
1.0 μM PBOX-15 (c, d),
10.0 μM nocodazole (e, f) or
4.0 μM paclitaxel (g, h) for
30 min and incubated on poly-L
lysine (a, c, e, g) or anti-LFA-1
(b, d, f, h) coated Permanox®
chamber slides for 4 h. After this
time, the medium was carefully
removed and cells were fixed in
3% PFA. Cells were incubated
with rabbit polyclonal anti-
detyrosinated tubulin antibody
for 1 h and then with Alexa488
conjugated anti-rabbit secondary
antibody for further 1 h at room
temperature. After washing, nu-
clei of the cells were stained
with Hoechst (blue). Detyrosi-
nated tubulin (Glu-tubulin;
green) was visualized by confo-
cal microscopy using a 100X oil
immersion lens. Arrow indicates
clearly distinguishable MTOC.




The morphological changes in cells exposed to PBOX-
15 were similar to those induced by two other MT-targeting
drugs, paclitaxel and nocodazole. However, paclitaxel is
known to cause microtubule stabilization, whereas nocoda-
zole causes microtubule depolymerization. It has been
revealed in earlier studies from our group that PBOX-15
possesses anti-microtubule activity, as PBOX-15 treatment
disrupted microtubule networks [21]. Specific anti-micro-
tubule effect of PBOX-15 has also been proved in vitro
using cell-free tubulin polymerization assay [21]. The
disruption to the microtubules following treatment with
PBOX-15 was similar to that elicited by nocodazole.
Increasing concentrations of nocodazole and other known
tubulin depolymerizers are known to kinetically ‘cap’ the
actively growing plus end of microtubules, preventing
growth and, thus, leading ultimately to disassembly of the
microtubules [30]. Both PBOX-15 and nocodazole resulted
in a dramatic destruction of the complex MT network of
the cell, detected as an intricate mesh of microtubules in the
vehicle control cells. The effect of PBOX-15 upon the
microtubule network was distinct to that elicited by
treatment with paclitaxel. Paclitaxel, a known microtubule
polymerizer, causes an increase in microtubule mass and a
consequently distinctive bundling of the microtubules. In
Fig. 8 Ex vivo determination of tubulin polymerization due to
PBOX-15 treatment in resting and LFA-1 stimulated T-cells. Hut78
cells were pretreated with either vehicle [0.1% (v/v) ethanol] (control)
or 1.0 μM PBOX-15 for 30 min, stimulated with (S) or without (R)
anti-LFA-1 for 4 h and lysed. Unpolymerized and polymerized protein
fractions were separated by centrifugation and collected as supernatant
and pellet respectively. Samples were separated by SDS-PAGE, and
after western blotting probed with anti-α-tubulin or GAPDH (as a
loading control) antibody (a). Relative densitometric analysis of the
individual band was performed and presented (b). Data are mean ±
SEM of three independent experiments. * p<0.05
Fig. 7 Effect of PBOX-15 on post-translational modifications of
tubulin in resting and LFA-1 stimulated T-cells. Hut78 cells were
pretreated with either vehicle [0.1% (v/v) ethanol] (control) or 1.0 μM
PBOX-15 for 30 min, stimulated with (S) or without (R) anti-LFA-1
for 4 h and lysed. Equal amounts of cell lysates (20 μg each) were
separated by SDS-PAGE, and after western blotting probed with anti-
α-tubulin, anti-acetylated tubulin (Ac-tubulin), anti-tyrosinated tubulin
(Tyr-tubulin) or GAPDH (as a loading control) antibody (a). Relative
densitometric analysis of the individual band was performed and
presented (b). Data are mean ± SEM of three independent experi-
ments. *p<0.05 with respect to respective controls
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contrast, PBOX-15 targets the microtubule network of the
cell and causes its disruption via microtubule depolymer-
ization. This strongly indicates that effect of PBOX-15 on
depolymerization of tubulin was direct, thus, causing
inhibition of subsequent cell migration when stimulated
with LFA-1.
In addition to being expressed as multiple gene-encoded
isoforms, tubulins undergo a wealth of covalent post-
translational modifications that are thought to modulate
the functions and localization of MTs within the cell [31].
α-Tubulin undergoes a reversible process by which the C-
terminal tyrosine residue is removed and re-added. This
cycle of detyrosination and tyrosination is evolutionarily
conserved [32]. Whereas the reversible detyrosination–
tyrosination cycle of α-tubulin has been studied extensively
[27] and implicated in regulating various aspects of cell
biology, the precise biological function of this highly
specific post-translational modification has remained poorly
characterized. Heterogeneity of detyrosinated and tyrosi-
nated forms of α-tubulin in the MTs may be required for
coordination and differential interaction of MTs with MT-
associated proteins [33] and motor proteins such as kinesin
and dynein [34]. Acetylation of α-tubulin is mostly
associated with stable microtubular structures, e.g., axo-
nemes, and it occurs after MT assembly [27]. Although the
enzyme that is responsible for α-tubulin acetylation
‘tubulin acetyltransferase’ is not fully characterized, two
enzymes that catalyze the opposing reaction, i.e., deacety-
lation (histone deacetylase-6 and histone deacetylase
SIRT2) have been recently described [27]. A role of tubulin
acetylation in cell motility has been proposed on the basis
of that histone deacetylase-6 overexpression increases the
chemotactic movement of NIH-3T3 cells, whereas inhibi-
tion of histone deacetylase-6 inhibited cell migration [27].
Whether this reflects a direct effect of acetylation on MT
stability and dynamics remains unsolved [27]. Further work
is needed to dissect the mechanism by which tubulin
acetylation influences motility. Thus, apart from effect of
PBOX-15 on tubulin polymerization which plays a leading
role in T-cell migration, post-translational modifications of
tubulin could potentially represent novel therapeutic targets.
Our data clearly indicate that post-transcriptional modifica-
tions of tubulin are functionally important for T-cell
migration. In this study, we examined the effects of
PBOX-15 on the post-translational modification of α-
tubulin in T-cells leading to inhibition of their migration.
We demonstrated that the tyrosinated form of α-tubulin is
reduced after PBOX-15 treatment. Moreover, the acetylated
form of tubulin was also reduced by PBOX-15 treatment.
Therefore, the data suggest that PBOX-15, in addition to its
possible direct tubulin targeting, can also affect post-
translation modifications of this crucial cytoskeletal protein.
Effect of PBOX-15 on other signaling processes could have
additional and discrete consequences for cell migration that
were not explored in this study. A series of focused
experiments are presently being carried out to characterize
the signaling events in T-cells following anti-LFA-1
exposure in detail.
While the ability of PBOX-15 to induce apoptosis of T-
cells has been demonstrated, no information was available
about the ability of PBOX-15 to regulate other T-cell
functions, such as migration. Here, we propose a novel anti-
inflammatory effect of PBOX-15 by reducing T-cell
migration. We have used our in vitro model for T-cell
migration which has been well characterized [3, 6, 8, 24].
The in vivo efficacy of PBOX-15 on the LFA-1 integrin-
induced migration was also confirmed using PBTLs
isolated from a healthy donor. Therefore, the results
obtained might be extrapolated in a broader context.
MT-targeting anticancer drugs (e.g., taxol) also possess
anti-inflammatory properties [35]. From this perspective,
one can expect direct beneficial effect of the new PBOX-15
compound in leukemic cancers arising from the cells of
immune system. However, the precise therapeutic
approaches and schedules will certainly have to be optimized
by clinicians in order to prevent the possibility of uncon-
trolled immune suppression and/or resulting infectious
complications.
In conclusion, we have demonstrated that PBOX-15 is
capable of inhibiting T-cell migration by dramatically
altering MT dynamics. Microtubules are important for
many aspects of mammalian cell responses including
growth, migration, and signaling. The clinical efficacy of
anti-microtubule agents is well established, although in-
creasing evidence of resistance to these agents has
prompted the search for new agents with a similar
mechanism. Thus, the novel MT-targeting compound
PBOX-15 may be used therapeutically to downregulate
inflammatory reactions, such as those associated with
autoimmunity and allergy. The ability of PBOX-15 to
inhibit T-cell migration explains its beneficial effects in
process where T-cell play an important role and suggests
that PBOX-15 may be used therapeutically with chronic
inflammatory diseases. Although the various molecular
mechanisms involved in disrupting the immunosuppressive
network for cancer patients still require clarification, we are
approaching the time when it may be possible to use
immunotherapy as a primary systemic cancer treatment.
Therapeutic agents that target cytoskeletal proteins and are
effective in inhibiting cell migration can open new horizons
in the treatment of cancer and cancer metastatic spreading.
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